Robert Olstein
Olstein Capital Management
Robert Olstein Integra LifeSciences Holdings stake
total: 342
Olstein Capital Management IART trades
- Total transactions:
- 31
- New positions:
- 2
- Sold out:
- 2
- Added:
- 20
- Reduced:
- 7
- Held since:
- 2019 Q2
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, Robert Olstein doesn't hold any Integra LifeSciences Holdings (IART) shares. To date, the estimated cost basis is nearly $32.45 for "buy" trades and estimated average "sell" price is $17.5. Olstein Capital Management first purchased IART in 2014 Q1, initially acquiring 98,000 shares. Robert Olstein later completely sold out the position and invested in Integra LifeSciences Holdings again in 2019 Q2. Since the initial investment in Integra LifeSciences Holdings (IART), Olstein Capital Management has made 30 more transactions.
When did Robert Olstein sell Integra LifeSciences Holdings (IART)?
Robert Olstein sold off the entire Integra LifeSciences Holdings (IART) position in 2026 Q1.
When did Robert Olstein buy Integra LifeSciences Holdings (IART)?
Robert Olstein first invested in Integra LifeSciences Holdings (IART) in 2014 Q1 at the reported quarter-end price of $23.00 per share.
What's the cost basis of Olstein Capital Management's IART stake?
The estimated cost basis for Integra LifeSciences Holdings (IART) stake is around $32.45 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $32.45
- Weighted AVG sell price:
- $17.50
Robert Olstein's historical trades in Integra LifeSciences Holdings
31 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
0
|
$12.42
|
|
-100% (-123,000)
|
-0.31%
|
|
2025 Q4
|
0.31%
|
123,000
|
$12.42
|
$1,528,000
|
-11.51% (-16,000)
|
-0.04%
|
|
2025 Q3
|
0.38%
|
139,000
|
$14.33
|
$1,992,000
|
+2.96% (+4,000)
|
+0.01%
|
|
2025 Q2
|
0.31%
|
135,000
|
$12.27
|
$1,656,000
|
+37.76% (+37,000)
|
+0.09%
|
|
2025 Q1
|
0.40%
|
98,000
|
$21.99
|
$2,155,000
|
-26.32% (-35,000)
|
-0.14%
|
|
2024 Q4
|
0.53%
|
133,000
|
$22.68
|
$3,016,000
|
-14.19% (-22,000)
|
-0.08%
|
|
2024 Q3
|
0.48%
|
155,000
|
$18.17
|
$2,816,000
|
+37.17% (+42,000)
|
+0.13%
|
|
2024 Q2
|
0.59%
|
113,000
|
$29.14
|
$3,293,000
|
+13.00% (+13,000)
|
+0.07%
|
|
2024 Q1
|
0.58%
|
100,000
|
$35.45
|
$3,545,000
|
+35.14% (+26,000)
|
+0.15%
|
|
2023 Q4
|
0.54%
|
74,000
|
$43.55
|
$3,223,000
|
+4.23% (+3,000)
|
+0.02%
|
|
2023 Q3
|
0.46%
|
$38.18
|
+2.90% (+2,000)
|
|||
|
2023 Q2
|
0.46%
|
$41.13
|
+53.33% (+24,000)
|
|||
|
2023 Q1
|
0.40%
|
$57.40
|
-2.17% (-1,000)
|
|||
|
2022 Q3
|
0.33%
|
$42.37
|
+2.22% (+1,000)
|
|||
|
2022 Q2
|
0.36%
|
$54.02
|
+7.14% (+3,000)
|
|||
|
2022 Q1
|
0.34%
|
$64.26
|
-6.67% (-3,000)
|
|||
|
2021 Q4
|
0.36%
|
$67.00
|
+9.76% (+4,000)
|
|||
|
2021 Q3
|
0.34%
|
$68.49
|
-10.87% (-5,000)
|
|||
|
2020 Q4
|
0.48%
|
$64.91
|
+6.98% (+3,000)
|
|||
|
2020 Q3
|
0.37%
|
$47.21
|
+19.44% (+7,000)
|
|||
|
2020 Q2
|
0.32%
|
$47.00
|
+13.53% (+4,290)
|
|||
|
2020 Q1
|
0.31%
|
$44.65
|
+51.00% (+10,710)
|
|||
|
2019 Q4
|
0.19%
|
$58.29
|
+133.33% (+12,000)
|
|||
|
2019 Q3
|
0.08%
|
$60.11
|
+12.50% (+1,000)
|
|||
|
2019 Q2
|
0.07%
|
$55.88
|
new
|
|||
|
2015 Q3
|
0.00%
|
$33.68
|
-100% (-116,000)
|
|||
|
2015 Q2
|
0.41%
|
$33.68
|
-3.33% (-4,000)
|
|||
|
2015 Q1
|
0.40%
|
$30.82
|
+5.26% (+6,000)
|
|||
|
2014 Q4
|
0.38%
|
$27.11
|
+3.64% (+4,000)
|
|||
|
2014 Q2
|
0.35%
|
$23.53
|
+12.24% (+12,000)
|
|||
|
2014 Q1
|
0.31%
|
$23.00
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.